Jeremy Grantham's REGN Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 56,704 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $43.77 M, representing 0.11% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Jeremy Grantham has maintained a strategic position in REGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2020, adding 27,700 shares. Largest reduction occurred in Q3 2013, reducing 30,600 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -4,770 | Reduce 7.76% | 56,704 | $771.87 |
| Q3 2025 | -3,809 | Reduce 5.83% | 61,474 | $562.27 |
| Q2 2025 | -18,047 | Reduce 21.66% | 65,283 | $525.00 |
| Q1 2025 | +20,351 | Add 32.31% | 83,330 | $634.23 |
| Q4 2024 | +10,982 | Add 21.12% | 62,979 | $712.33 |
| Q3 2024 | -5,267 | Reduce 9.20% | 51,997 | $1051.24 |
| Q2 2024 | -596 | Reduce 1.03% | 57,264 | $1051.03 |
| Q1 2024 | -9,240 | Reduce 13.77% | 57,860 | $962.49 |
| Q4 2023 | +9,160 | Add 15.81% | 67,100 | $878.29 |
| Q3 2023 | +5,036 | Add 9.52% | 57,940 | $822.96 |
| Q2 2023 | -14,238 | Reduce 21.21% | 52,904 | $718.54 |
| Q1 2023 | -4,000 | Reduce 5.62% | 67,142 | $821.67 |
| Q4 2022 | +17,142 | Add 31.74% | 71,142 | $721.49 |
| Q3 2022 | -2,400 | Reduce 4.26% | 54,000 | $688.87 |
| Q2 2022 | +8,500 | Add 17.75% | 56,400 | $591.13 |
| Q1 2022 | +500 | Add 1.05% | 47,900 | $698.41 |
| Q4 2021 | -1,900 | Reduce 3.85% | 47,400 | $631.52 |
| Q3 2021 | +800 | Add 1.65% | 49,300 | $605.17 |
| Q2 2021 | +6,900 | Add 16.59% | 48,500 | $558.54 |
| Q1 2021 | +13,444 | Add 47.75% | 41,600 | $473.15 |
| Q4 2020 | +27,700 | Add 6074.56% | 28,156 | $483.09 |
| Q2 2020 | +456 | New Buy | 456 | $622.81 |
| Q3 2019 | -11,100 | Sold Out | 0 | $0.00 |
| Q2 2019 | +10,600 | Add 2120.00% | 11,100 | $312.97 |
| Q1 2019 | +500 | New Buy | 500 | $410.00 |
| Q3 2013 | -30,600 | Sold Out | 0 | $0.00 |
| Q2 2013 | +30,600 | Add 0.00% | 30,600 | $224.87 |
Jeremy Grantham's Regeneron Pharmaceuticals Investment FAQs
Jeremy Grantham first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 30,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Regeneron Pharmaceuticals, Inc. (REGN) for 28 quarters since Q2 2013.
Jeremy Grantham's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q2 2013, adding 30,600 shares worth $6.88 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 56,704 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $43.77 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.11% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 83,330 shares, as reported at the end of Q1 2025.